8,903 trials (keyword fallback)
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
Infertility
Primary: Oocytes — 19; 47 oocytes
Infertility
Primary: Total Number of Oocytes — 12.4; 12.1 Number of oocytes
Ovarian Neoplasms
Primary: Purchase Behaviours (Purchase of Items) — 3.2; 2.0; 5.9; 4.3 number of items purchased — p=<0.001
HIV-1 Infection
Primary: Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine — 53.9; 54.6 µM*hr
Ovarian Neoplasms · Fallopian Tube Neoplasms · Primary Peritoneal Neoplasms
Primary: 6 Month Progression Free Survival — 0 Participants
Polycystic Ovary Syndrome
Primary: Aim 1: HCG-stimulated Testosterone Area Under the Curve — 4458; 7775 Nonograms*Hour per Deciliter (ng*hr/dL) — p=<0.004
Ovarian Cancer · Primary Peritoneal Cancer · Serous Carcinoma Cancer
Primary: Percentage of Participants With an Overall Response Rate — 9.5; 5.6; 0; 11.8 percentage of participants
Healthy
Primary: Serum 25-hydroxyvitamin D — 26.7; 22.4 ng/mL — p=0.003
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Viral Response 12 Weeks After Completing Study Therapy (SVR12) — 90.0; 100.0 Percentage of participants
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Progression-free Survival — 2.9; 5.3 months — p=0.019
Obesity
Primary: Change in Insulin Resistance After 12 Weeks of Vitamin D3 Supplementation — 0.01; -0.27 HOMA score — p=0.95
Type 2 Diabetes · Overt Diabetic Nephropathy
Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr
Renal Insufficiency · Renal Impairment
Primary: Geometric Least Squares Mean Area Under the Plasma Drug Concentration-time Curve From Time Zero to Infinity (AUC0-∞) Following a Single IV Dose of Sugammadex — 339; 151…
Ovarian Cancer
Primary: Colony Stimulating Factor (CSF-1) Expression in Ovarian Endosalpingiosis — 5; 130; 50 Modified H-Score — p=0.012